Test Detects Anti-HIV-1 and Anti-HIV-2 Antibodies

A diagnostic assay has been developed for the detection of antibodies to human immunodeficiency virus types 1 and/or 2 (anti-HIV-1 and anti-HIV-2).

The new Vitros Anti-HIV 1+2 assays can be run in a fully automated, random access format on the Vitros ECi/ECiQ immunodiagnostic system, with results readily available in less than 50 minutes. The tests can be run at any time, in any order, and with other types of tests. The features of automation and random access increase productivity and efficiency in the laboratory.

Approximately 1,039,000 to 1,185,000 people in the United States are living with HIV/AIDS, with 24-27 % undiagnosed and unaware of their HIV infection. Costs associated with unrecognized or late-recognized HIV infection are growing.

Ortho-Clinical Diagnostics (Rochester, NY, USA) announced that the U.S. Food and Drug Administration (FDA; Rockville, MD) approved its new diagnostic assay for the detection of antibodies to HIV-1 and -2 on the Vitros immunodiagnostic system. The assay was co-developed with Chiron, a business of Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA, USA). The FDA approval and availability to laboratories in the United States, Puerto Rico, and U.S. territories marks the first anti-HIV 1+2 test capable of being run in full random access along swith other tests and providing immediate results upon test completion.


Related Links:
Ortho-Clinical Diagnostics
Chiron
Novartis Vaccines and Diagnostics